Herceptin
Payments companies reported to CMS as associated with Herceptin. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Herceptin, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Herceptin
These are the largest totals companies reported as associated with Herceptin. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Joyce O'Shaughnessy | Dallas, TX | Medical Oncology | $9,453.20 |
| Yuan Yuan | Pasadena, CA | Medical Oncology | $5,709.44 |
| Ian Krop | New Haven, CT | Medical Oncology | $4,527.04 |
| Joseph Sparano | Bronx, NY | Medical Oncology | $4,069.44 |
| Vijayakrishna Gadi | Seattle, WA | Medical Oncology | $4,069.44 |
| Abirami Sivapiragasam | Syracuse, NY | Hematology & Oncology | $3,957.04 |
| Jason Mouabbi | Houston, TX | Medical Oncology | $3,882.63 |
| Shanu Modi | New York, NY | Medical Oncology | $3,821.57 |
| Nan Chen | Chicago, IL | Hematology & Oncology | $3,456.29 |
| Cynthia Ma | Saint Louis, MO | Medical Oncology | $3,435.54 |
Prescribed Herceptin?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.